Quantum Genesis AI Corp. is focused on developing engineered enzymes using quantum mechanics and molecular modeling to improve pharmaceutical API synthesis, particularly ibuprofen. Despite progressing intellectual property formalization and proprietary technological approaches, the company reported no revenues as of FY2025 and operates with minimal personnel. Its licensing business model reduces manufacturing risks but depends heavily on forming strategic partnerships amid a critical liquidity crisis that raises going-concern concerns.